Clinical Trial Update: ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial compares Naptumomab estafenatox plus interferon-alpha versus interferon-alpha alone in advanced renal cell carcinoma; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Interferon-alpha (interferon alpha)
• Naptumomab Estafenatox (naptumomab estafenatox)

Snippet

Sponsor: Active Biotech AB | Conditions: Renal Cell Carcinoma | Phase 2, Phase 3 | Status: COMPLETED